SMILE helped some patients with interocular astigmatic axis discordance achieve predictable correction, according to a study in Journal of Refractive Surgery.Manrong Yu, MD, PhD, of Fudan University, Shanghai, and colleagues wrote that previous studies…
Advice on the Challenges in Managing Sjögren Disease
Dr Teja Kapoor urges early-career clinicians not to underestimate Sjögren’s disease, which requires thorough testing and multidisciplinary collaboration. Medscape
Overcoming Barriers in Sjögren Disease Care
Dr Teja Kapoor explores how cultural sensitivity and awareness can overcome barriers to timely Sjögren disease management in diverse communities. Medscape
GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (“GenSight Biologics” or the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for ret…
GenSight Biologics publie sa situation de trésorerie au 31 décembre 2025 et fait un point sur son activité
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (« GenSight Biologics » ou la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de…
Ollin Biosciences Announces Positive Topline Data with Superior Outcomes from a Randomized Head-to-Head Study of OLN324 Compared to Faricimab (Vabysmo®) in Diabetic Macular Edema and Wet Age-Related Macular Degeneration
AUSTIN, Texas–(BUSINESS WIRE)–Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced positive topline results from its randomized, head-to-head Phase 1b JADE clin…